Although TAC alters the expression of these miRNAs, to validate expression of targets observed in DCM samples, we used miRNA 7 in our experimental studies as it is 1) a novel miRNA identified in our profiling, 2) it targets EGFR growth family receptor ERBB2, a critical player cardiac hypertrophic response [29, 30] and is one of the miRNAs down regulated early post-TAC. This evidence concerns the gene ERBB2 and persistent truncus arteriosus.